What happens when you take azathioprine with allopurinol?
Azathioprine is a thiopurine prodrug used as an immunosuppressant in inflammatory bowel disease (Crohn's, ulcerative colitis), autoimmune hepatitis, lupus, after organ transplantation, and in several other conditions. After absorption, it is converted to 6-mercaptopurine (6-MP), which is then partitioned among several pathways. Two routes deactivate the drug: thiopurine methyltransferase (TPMT) methylates it into inactive metabolites, and xanthine oxidase oxidizes it to 6-thiouric acid for renal excretion. A third route, activation, converts a fraction of 6-MP into 6-thioguanine nucleotides (6-TGN), which are the active immunosuppressive species that get incorporated into DNA and produce the drug's effect (and its toxicity).
Allopurinol is a potent inhibitor of xanthine oxidase, used to lower uric acid in gout and tumor lysis syndrome. When allopurinol blocks xanthine oxidase, the inactivation pathway for 6-MP is shut down. More 6-MP is shunted into the activation pathway, raising 6-TGN levels 3 to 4 fold. The result is dramatically increased immunosuppression and bone marrow suppression at any given azathioprine dose.
The interaction is well-characterized, dose-related, and has caused fatalities. The FDA azathioprine label carries a specific warning that concurrent use of allopurinol requires reducing the azathioprine dose to one-quarter or one-third of the usual dose, with frequent blood count monitoring.
Why is this important?
Myelosuppression from azathioprine toxicity can be severe and rapid. Patients can develop neutropenia, thrombocytopenia, and anemia within days to weeks of starting allopurinol on top of stable azathioprine therapy. Severe neutropenia leads to sepsis, severe thrombocytopenia to spontaneous bleeding, and severe anemia to transfusion dependence. Pancytopenia, in which all three lineages collapse, is potentially fatal.
Hepatotoxicity is also a risk. Elevated 6-TGN and 6-methyl-mercaptopurine levels can produce transaminase elevations, cholestasis, and in rare cases acute liver failure. Mucositis, severe nausea, and pancreatitis are other recognized features of azathioprine toxicity.
The danger is amplified in patients with reduced TPMT activity, either from inherited polymorphisms or from drug effects. About 0.3% of the population has homozygous TPMT deficiency, which alone causes life-threatening myelosuppression at standard azathioprine doses; in these patients, even a small additional allopurinol effect is catastrophic. The newer thiopurine-relevant variant NUDT15, common in East and South Asian populations, has similar implications.
An interesting twist is that the interaction is sometimes used intentionally. In inflammatory bowel disease, some patients are poor responders to azathioprine because they shunt too much 6-MP into the inactive methylated pathway, with high 6-MMP levels causing hepatotoxicity and low 6-TGN levels providing inadequate efficacy. Adding low-dose allopurinol (50-100 mg daily) with a reduced azathioprine dose (25-33% of usual) redirects metabolism toward the active 6-TGN pathway and improves response. This is a specialized strategy used by IBD specialists with close monitoring and TPMT/NUDT15 genotyping, not a casual co-prescription.
What should you do?
If you are on azathioprine and your clinician is considering allopurinol for gout, ask whether an alternative is feasible. Lifestyle modification, urate-lowering through dietary change, and non-xanthine-oxidase drugs like probenecid or lesinurad may be options for some patients. If allopurinol is essential, the azathioprine dose must be reduced to 25-33% of usual and complete blood counts should be checked weekly for the first month, then at least monthly.
If you are on allopurinol and azathioprine is being added, the same dose reduction and monitoring apply. Make sure both prescribers know about each other and that pharmacy records reflect both medications. Single-system electronic medical records usually flag this interaction, but disconnected pharmacies (separate prescribers, mail-order plus retail) can miss it.
Get TPMT and NUDT15 genotype or phenotype testing before starting any thiopurine, especially if combination with allopurinol is being considered. Patients with intermediate or low activity need substantially lower starting doses, and combination with allopurinol is hazardous.
Watch for early signs of toxicity: unusual bruising or bleeding, mouth sores, fever, fatigue, jaundice, or right upper quadrant pain. Stop the medications and contact your prescriber urgently if any of these appear, especially in the first six weeks of combined therapy.
Febuxostat (Uloric, Adenuric) is another xanthine oxidase inhibitor and carries the same interaction warning. Do not assume febuxostat is safer than allopurinol with azathioprine; the manufacturer label specifically lists this combination as contraindicated.
Which specific products are affected?
The interaction applies to azathioprine (Imuran, Azasan, generic azathioprine tablets and injection) and to 6-mercaptopurine (Purinethol, Purixan, generic 6-MP), which is the active metabolite and shares the same xanthine oxidase clearance pathway. Both immunosuppressive and oncologic uses (6-MP is used in maintenance therapy for acute lymphoblastic leukemia) are affected, though the management strategies differ.
Xanthine oxidase inhibitors that interact include allopurinol (Zyloprim, Aloprim, generic) and febuxostat (Uloric, Adenuric). The interaction is a class effect; switching between them does not avoid the problem. Topiroxostat, used in some countries, has the same warning.
Other gout treatments without xanthine oxidase inhibition are safer with thiopurines. Probenecid acts at the kidney tubule, colchicine works through microtubule effects, and IL-1 antagonists like canakinumab work through cytokine blockade. None of them produce the catastrophic interaction seen with allopurinol or febuxostat.
The bottom line
Combining azathioprine or 6-mercaptopurine with allopurinol or febuxostat without dose adjustment can cause fatal pancytopenia. If the combination is necessary, reduce azathioprine to 25-33% of the usual dose, check TPMT and NUDT15 genotype, and monitor blood counts weekly initially. Whenever possible, choose a non-xanthine-oxidase gout treatment instead. Tell every prescriber and pharmacy about both medications.